查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1956793

肺動脈高壓市場分析及預測（至2035年）：按類型、產品、服務、技術、組件、應用、設備、最終用戶及解決方案分類

Pulmonary Arterial Hypertension Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Device, End User, Solutions
出版日期: | 出版商: Global Insight Services | 英文 389 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

肺動脈高壓市場預計將從2024年的77億美元成長到2034年的128億美元，複合年成長率約為5.5%。肺動脈高壓（PAH）市場涵蓋用於治療肺動脈高血壓（其特徵是肺動脈狹窄或阻塞）的治療方法。這些藥物包括內皮素受體拮抗劑、5型磷酸二酯酶抑制劑和前列腺環素類似物。 PAH市場的成長預計將得益於盛行率的上升、診斷技術的進步以及新型治療方法的開發。對個人化醫療和聯合治療的關注帶來了盈利的市場機會，而監管支持也將進一步推動市場擴張。

由於標靶治療的進步和公眾意識的提高，肺動脈高壓 (PAH) 市場預計將迎來顯著成長。在藥物類別方面，前列腺環素及其類似物佔據主導地位，其在改善患者預後方面的卓越療效使其表現突出。內皮素受體拮抗劑則位居第二，因為它們能夠提高運動能力並延緩疾病進展。在給藥途徑方面，口服療法因其便利性和更高的患者依從性而佔據主導地位。腸外給藥雖然便利性稍遜，但由於其在重症病例中起效迅速，仍十分重要。在分銷管道方面，醫院藥房處於領先地位，這反映了對專業護理和監測的需求。隨著口服療法的廣泛應用，零售藥局的重要性也日益凸顯。此外，市場也受到聯合治療研究的推動，這些研究有望提高治療效果和患者生活品質。這種充滿活力的市場格局為相關人員提供了盈利的機會。

市場區隔
類型 特發性、遺傳性、藥物或毒素誘發性、結締組織疾病相關、HIV感染相關、門靜脈高壓相關、先天性心臟疾病相關
產品 內皮素受體拮抗劑、磷酸二酯酶5抑制劑、前列腺環素及其類似物、可溶性鳥苷酸環化酶促效劑、鈣離子通道阻斷劑
服務 診斷服務、諮詢服務、治療服務、監測服務、復健服務
科技 口服、靜脈注射注射、吸入、皮下注射
成分 活性藥物成分、添加物、包裝材料
目的 適用於醫院、診所、居家醫療保健以及研發
裝置 吸入器、輸液幫浦、診斷設備
最終用戶 醫院、專科診所、居家醫療機構、研究機構
解決方案 病患管理系統、數據分析解決方案、遠端醫療解決方案

肺動脈高壓市場呈現市場佔有率分佈多元化、定價策略動態變化以及新產品快速上市的特徵。具競爭力的定價和創新治療方法是推動市場動態的關鍵因素，其核心在於改善患者預後。市場正朝著個人化醫療的方向發展，新興治療方法也日益受到重視。北美和歐洲引領著這一趨勢，而亞太地區則展現出巨大的成長潛力。競爭基準分析揭示了充滿活力的競爭環境，主要企業積極尋求策略聯盟和併購以鞏固其市場地位。監管影響至關重要，嚴格的指導方針影響醫藥品認證過程和打入市場策略。北美和歐洲的法規環境設定了高標準，企業必須遵守這些標準才能實現市場滲透。這種競爭和監管框架凸顯了創新方法和適應能力的重要性，不僅為肺動脈高壓領域的永續成長帶來了挑戰，也帶來了機會。

主要趨勢和促進因素：

肺動脈高壓 (PAH) 市場正經歷著蓬勃發展，這主要得益於醫學研發和治療方法創新方面的顯著進步。其中一個關鍵趨勢是針對 PAH 潛在病理病理學的新型藥物療法的研發，這有望提高治療效果和患者預後。此外，個人化醫療也日益受到重視，根據患者個別情況量身定做的治療方案能夠提升整體介入措施的有效性。另一個趨勢是對數位健康技術的投資不斷成長，包括遠端監測和遠端醫療解決方案，這些技術有助於改善疾病管理並提高患者對治療方案的依從性。人工智慧在診斷流程中的應用也增強了早期檢測和治療方案製定的準確性。此外，以病人為中心的照護模式也日益受到關注，這些模式優先考慮生活品質和全面的健康管理。成長要素包括公眾意識和診斷率的提高，以及結締組織疾病和先天性心臟疾病等風險因素的增加。對孤兒藥的監管支持正在促進進一步的創新和新型治療方法的市場准入。新興市場醫療基礎設施不斷完善，先進療法的可及性日益提高，蘊藏著許多機會。能夠掌握這些趨勢和促進因素的公司，將有望實現顯著成長並佔據市場主導。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 特發性
    • 遺傳
    • 藥物和毒素誘導
    • 與結締組織疾病相關
    • 與愛滋病毒感染有關
    • 與門靜脈高壓相關
    • 與先天性心臟疾病相關
  • 市場規模及預測：依產品分類
    • 內皮素受體拮抗劑
    • 磷酸二酯酶5抑制劑
    • 前列腺環素和前列腺環素類似物
    • 可溶性鳥苷酸環化酶促效劑
    • 鈣離子通道阻斷劑
  • 市場規模及預測：依服務分類
    • 診斷服務
    • 諮詢服務
    • 治療服務
    • 監控服務
    • 復健服務
  • 市場規模及預測：依技術分類
    • 口服
    • 靜脈注射
    • 吸入給藥
    • 皮下注射
  • 市場規模及預測：依組件分類
    • 活性成分
    • 添加劑
    • 包裝材料
  • 市場規模及預測：依應用領域分類
    • 醫院用途
    • 臨床應用
    • 居家醫療用途
    • 研究與開發
  • 市場規模及預測：依設備分類
    • 吸入器
    • 點滴幫浦
    • 診斷設備
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 居家醫療環境
    • 研究所
  • 市場規模及預測：按解決方案分類
    • 病患管理系統
    • 數據分析解決方案
    • 遠端醫療解決方案

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • United Therapeutics
  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Bayer Health Care
  • Glaxo Smith Kline
  • Arena Pharmaceuticals
  • Reata Pharmaceuticals
  • Acceleron Pharma
  • Liquidia Technologies
  • Aerami Therapeutics
  • Altavant Sciences
  • Complexa
  • Mann Kind Corporation
  • Phase Bio Pharmaceuticals
  • Insmed Incorporated
  • Merck Group
  • Cytokinetics
  • Tenax Therapeutics
  • Visterra
  • Pulmokine

第9章：關於我們

簡介目錄
Product Code: GIS21396

Pulmonary Arterial Hypertension Market is anticipated to expand from $7.7 billion in 2024 to $12.8 billion by 2034, growing at a CAGR of approximately 5.5%. The Pulmonary Arterial Hypertension (PAH) Market encompasses treatments targeting high blood pressure in the arteries of the lungs, characterized by narrowing or blockage. This market includes endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. Driven by rising prevalence, advancements in diagnostics, and novel therapeutic developments, the PAH market is poised for growth. Emphasis on personalized medicine and combination therapies presents lucrative opportunities, while regulatory support further enhances market expansion.

The Pulmonary Arterial Hypertension (PAH) Market is poised for substantial growth, driven by advancements in targeted therapies and increasing awareness. The drug class segment is dominated by prostacyclin and prostacyclin analogs, which are top performers due to their efficacy in improving patient outcomes. Endothelin receptor antagonists follow closely, benefiting from their ability to enhance exercise capacity and delay disease progression. Within the route of administration segment, oral therapies lead, offering convenience and improved patient adherence. Parenteral administration, though less convenient, remains significant due to its rapid onset of action in severe cases. In the distribution channel segment, hospital pharmacies are at the forefront, reflecting the need for specialized care and monitoring. Retail pharmacies are gaining momentum as oral therapies become more prevalent. The market is further propelled by ongoing research into combination therapies, promising to enhance treatment efficacy and patient quality of life. This dynamic landscape presents lucrative opportunities for stakeholders.

Market Segmentation
TypeIdiopathic, Heritable, Drug and Toxin Induced, Associated with Connective Tissue Diseases, Associated with HIV Infection, Associated with Portal Hypertension, Associated with Congenital Heart Diseases
ProductEndothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, Soluble Guanylate Cyclase Stimulators, Calcium Channel Blockers
ServicesDiagnostic Services, Consultation Services, Treatment Services, Monitoring Services, Rehabilitation Services
TechnologyOral Administration, Intravenous Administration, Inhalation Administration, Subcutaneous Administration
ComponentActive Pharmaceutical Ingredients, Excipients, Packaging Materials
ApplicationHospital Use, Clinic Use, Homecare Use, Research and Development
DeviceInhalers, Infusion Pumps, Diagnostic Devices
End UserHospitals, Specialty Clinics, Homecare Settings, Research Organizations
SolutionsPatient Management Systems, Data Analytics Solutions, Telemedicine Solutions

The Pulmonary Arterial Hypertension market is characterized by a diverse landscape of market share distribution, dynamic pricing strategies, and a surge in new product launches. The competitive pricing and innovative therapies are pivotal in driving market dynamics, with a focus on improving patient outcomes. The market is witnessing a shift towards personalized medicine, with emerging therapies gaining traction. Notably, North America and Europe are at the forefront of these developments, while Asia-Pacific demonstrates significant growth potential. Competition benchmarking reveals a robust landscape, with key players actively engaging in strategic alliances and mergers to enhance their market standing. Regulatory influences play a critical role, with stringent guidelines impacting drug approval processes and market entry strategies. The regulatory environment in North America and Europe sets high standards, which companies must navigate to achieve market penetration. This competitive and regulatory framework underscores the need for innovative approaches and adaptability, offering both challenges and opportunities for sustained growth in the Pulmonary Arterial Hypertension sector.

Geographical Overview:

The Pulmonary Arterial Hypertension (PAH) market is witnessing notable growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by advanced healthcare infrastructure and significant investment in medical research. The presence of leading pharmaceutical companies further bolsters the market's expansion. Europe closely follows, with a strong focus on innovative therapies and robust healthcare systems that facilitate market growth. Asia Pacific is emerging as a lucrative region, propelled by increasing healthcare expenditure and rising awareness about PAH. Countries like China and India are at the helm, with substantial investments in healthcare infrastructure and research. These nations are poised to become key players in the PAH market. Latin America and the Middle East & Africa are also gaining traction. In Latin America, improving healthcare access and economic growth are driving market expansion. Meanwhile, the Middle East & Africa are recognizing the importance of addressing PAH, fostering new growth avenues in the region.

Global tariffs and geopolitical tensions are intricately influencing the Pulmonary Arterial Hypertension (PAH) market. In Japan and South Korea, reliance on imported pharmaceuticals is prompting strategic shifts towards domestic production and innovation. China's focus on self-reliance is accelerating its biopharmaceutical capabilities, while Taiwan leverages its robust biotech sector amid geopolitical uncertainties. The global PAH market is expanding, driven by increased prevalence and advancements in treatment, yet faces challenges from trade tensions and supply chain disruptions. By 2035, market growth will hinge on geopolitical stability and the resilience of supply networks. Middle East conflicts, impacting energy prices, could exacerbate supply chain vulnerabilities, influencing manufacturing costs and distribution timelines, thus shaping the strategic landscape for these East Asian nations.

Key Trends and Drivers:

The Pulmonary Arterial Hypertension (PAH) market is witnessing a dynamic evolution, driven by significant advancements in medical research and therapeutic innovations. A key trend is the development of novel drug therapies that target the underlying pathophysiology of PAH, offering improved efficacy and patient outcomes. This is complemented by an increasing emphasis on personalized medicine, where treatments are tailored to individual patient profiles, enhancing the overall effectiveness of interventions. Another trend is the growing investment in digital health technologies, including remote monitoring and telemedicine solutions, which facilitate better disease management and patient adherence to treatment regimens. The integration of artificial intelligence in diagnostic procedures is also enhancing early detection and treatment planning. Additionally, there is a heightened focus on patient-centric care models that prioritize quality of life and holistic health management. Drivers of the PAH market include rising awareness and diagnosis rates, as well as the increasing prevalence of risk factors such as connective tissue diseases and congenital heart conditions. Regulatory support for orphan drugs is further stimulating innovation and market entry of new therapies. Opportunities abound in emerging markets where healthcare infrastructure is improving, and access to advanced treatments is expanding. Companies that leverage these trends and drivers are well-positioned to achieve substantial growth and market leadership.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Idiopathic
    • 4.1.2 Heritable
    • 4.1.3 Drug and Toxin Induced
    • 4.1.4 Associated with Connective Tissue Diseases
    • 4.1.5 Associated with HIV Infection
    • 4.1.6 Associated with Portal Hypertension
    • 4.1.7 Associated with Congenital Heart Diseases
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Endothelin Receptor Antagonists
    • 4.2.2 Phosphodiesterase-5 Inhibitors
    • 4.2.3 Prostacyclin and Prostacyclin Analogs
    • 4.2.4 Soluble Guanylate Cyclase Stimulators
    • 4.2.5 Calcium Channel Blockers
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Diagnostic Services
    • 4.3.2 Consultation Services
    • 4.3.3 Treatment Services
    • 4.3.4 Monitoring Services
    • 4.3.5 Rehabilitation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Oral Administration
    • 4.4.2 Intravenous Administration
    • 4.4.3 Inhalation Administration
    • 4.4.4 Subcutaneous Administration
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Active Pharmaceutical Ingredients
    • 4.5.2 Excipients
    • 4.5.3 Packaging Materials
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Hospital Use
    • 4.6.2 Clinic Use
    • 4.6.3 Homecare Use
    • 4.6.4 Research and Development
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Inhalers
    • 4.7.2 Infusion Pumps
    • 4.7.3 Diagnostic Devices
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Hospitals
    • 4.8.2 Specialty Clinics
    • 4.8.3 Homecare Settings
    • 4.8.4 Research Organizations
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Patient Management Systems
    • 4.9.2 Data Analytics Solutions
    • 4.9.3 Telemedicine Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Device
      • 5.2.1.8 End User
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Device
      • 5.2.2.8 End User
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Device
      • 5.2.3.8 End User
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Device
      • 5.3.1.8 End User
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Device
      • 5.3.2.8 End User
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Device
      • 5.3.3.8 End User
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Device
      • 5.4.1.8 End User
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Device
      • 5.4.2.8 End User
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Device
      • 5.4.3.8 End User
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Device
      • 5.4.4.8 End User
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Device
      • 5.4.5.8 End User
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Device
      • 5.4.6.8 End User
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Device
      • 5.4.7.8 End User
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Device
      • 5.5.1.8 End User
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Device
      • 5.5.2.8 End User
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Device
      • 5.5.3.8 End User
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Device
      • 5.5.4.8 End User
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Device
      • 5.5.5.8 End User
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Device
      • 5.5.6.8 End User
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Device
      • 5.6.1.8 End User
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Device
      • 5.6.2.8 End User
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Device
      • 5.6.3.8 End User
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Device
      • 5.6.4.8 End User
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Device
      • 5.6.5.8 End User
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 United Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Actelion Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Gilead Sciences
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bayer Health Care
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Glaxo Smith Kline
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Arena Pharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Reata Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Acceleron Pharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Liquidia Technologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Aerami Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Altavant Sciences
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Complexa
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Mann Kind Corporation
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Phase Bio Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Insmed Incorporated
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Merck Group
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Cytokinetics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Tenax Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Visterra
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Pulmokine
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us